Introduction 1
Viral lung infections are an important cause of mortality and morbidity 2 worldwide (18). Respiratory syncytial virus (RSV) is the main cause of infantile 3 bronchiolitis and therefore infant hospitalisation, and is associated with asthma 4 and wheezing in later life (28, 29) . Studies in humans and animal models 5 emphasise the importance of host responses in the pathogenesis of RSV disease 6 (22) . 7
In humans, severe RSV disease is associated with increased Th2 8 responses and with mutations associated with increased transcription of the 9
Interleukin-4 (IL-4) gene (6) . An increased IL-4/ Interferon gamma (IFN-γ) ratio is 10 also seen in the nasal secretion of those infants with RSV lower respiratory tract 11 infection compared to those with milder upper respiratory tract infection (16). 12
Another type 2 cytokine, IL-9, has also been recently been found at high levels in 13 the airways of infants with severe bronchiolitis (17) . has also been shown to reduce cytotoxic T lymphocyte activity and reduce viral 21 clearance in some cases (1, 11) . 22 The pattern of response to RSV can also be modified by prior exposure to 23 previous infections or vaccination with RSV antigens. Primary infection inducesTh1 responses (14) , and vaccination that enhances Th1 responses tend to be 1 associated with reduced disease during infection (30). Expression of RSV G, F, 2 or M2 result in: T-helper 2 cell expansion and eosinophilia (31); T-helper 1 cell 3 expansion and neutralising antibodies (33); or cytotoxic CD8 + T cell expansion 4 respectively (7). Immunization with formalin-inactivated RSV tends to induce Th2-5 biased responses and lung eosinophilia and enhanced disease during RSV 6 infection but this disease has recently been shown to be abrogated by the 7 reduction of carbonyl groups in the formalin treated vaccine (19) . 8 One possible approach to the development of novel and effective vaccines 9 is to use recombinant vectors to deliver host cytokines to the site of infection, with 10 the aim of programming protective, non-pathogenic host responses. For example, 11 expression of IFN-γ augments Th1 responses and suppress the Th2 responses, 12 whilst IL-4 has the opposite effect (21). However, the effects of cytokine 13 expression in viral vectors can lead to an adverse immune profile. For example, 14 recombinant mousepox (ectromelia) expressing IL-4 causes enhanced disease 15 and widens lethality to normally non-susceptible mouse strains. Such 16 recombinants cause fatal illness even in vaccinated hosts (15). 17 We have developed live recombinant RSV vectors expressing murine Th1 18 (IFN-γ) (4) or Th2 (IL-4) (5) cytokines. rRSV/IFN-γ shows many characteristics 19 that make it seem a good vaccine candidate, with attenuated growth in vivo and 20 good protection against subsequent viral replication (4). By contrast, the IL-4 21 expressing virus has been reported to cause delayed and reduced CD8 + T cell 22 responses without affecting viral clearance (5) . 23
To test and compare these recombinants further, we studied the 1 development of virus-specific immune responses to these two vectors in parallel 2 and examined the effects of secondary challenge with RSV or influenza A in 3 vaccinated mice. The results were unexpected: priming with rRSV/IFN-γ caused 4 marked weight loss during secondary challenge with wild-type RSV (wt RSV), 5 with enhanced lymphocytosis and an increase in virus-specific CD8 + T cells. By 6 contrast, rRSV/IL-4 did not cause any weight loss but did lead to significant lung 7 eosinophilia during secondary challenge with either RSV or, surprisingly, 8 influenza A infection.
Materials and Methods 1
Virus stocks & Mouse Infection. cDNA clones of mIL-4 and mIFN-γ were 2 modified to be flanked by the RSV gene start and gene end transcription signals 3
and XmaI sites. The PCR products were digested with XmaI and inserted into an 4
XmaI site that had been engineered into the G-F intergenic sequence of a cloned 5 cDNA of the RSV antigenome. The recombinant viruses were recovered by 6 cotransfection of the antigenomic plasmid and plasmids expressing the N, P, L, 7 and M2-1 support proteins into HEp-2 cells along with the recombinant MVA 8 vaccinia virus expressing T7 polymerase (4, 5) . 9
Wild type A2 strain RSV (wt RSV) and recombinant RSV virus expressing 10 cytometry were carried out as previously described (8) . For visualization of 22 peptide-specific, cytokine-producing CD8 + T cells, 2x10 6 lung cells were 23 incubated with the RSV peptide M2 82-90 (SYIGSINNI) for 5h in the presence of IL-1 2 (50 U/ml) and 10µg/ml Brefeldin A. Cells were analyzed on a BD LSR flow 2 cytometer collecting data on at least 50,000 events. Data was analysed using 3 WinList (Verity). 4 
5
Quantification of Viral RNA. Total RNA was extracted from the lung 6 using RNA stat-60 (AMS Biotech Ltd.) and cDNA was generated with random 7 hexamers using Omniscript RT (Qiagen). Real time PCR was carried out for the 8 RSV L gene using 900 nM forward primer (5'-9 GAACTCAGTGTAGGTAGAATGTTTGCA-3'), 300 nM reverse primer (5'-10 TTCAGCTATCATTTTCTCTGCCAAT-3') and 100 nM probe (5'-FAM-11 TTTGAACCTGTCTGAACAT-TAMRA-3') on an ABI Prism 7000 Sequence 12 Detection System as described (9). 13 
14
Cytokine ELISA. Cytokine levels were assessed from BAL supernatants 15 as described before (8 significance was calculated by ANOVA followed by Student's t test for p value as 18 described in the legends using GraphPad Prism software.
Results 1

Primary infection with recombinant RSV expressing IFN-γ or IL-4 2
BALB/c mice were infected with wt RSV, rRSV/IFN-γ or rRSV/IL-4. Using 3
TaqMan PCR to monitor viral load, we found that rRSV/IFN-γ was significantly 4 attenuated, showing an approximate 10 fold reduction in peak viral replication on 5 day 4 and day 8 respectively (Fig. 1A) , confirming previous findings using viral 6 plaque assay (4). On days 2 and 4, striking increases in the associated cytokines 7
were present in the bronchoalveolar lavage (BAL) fluid, indicating efficient in vivo 8 expression of IFN-γ or IL-4 ( Fig. 1B, C) . 9
Secondary infection with wild type RSV of mice primed with recombinant 10
RSV expressing IFN-γ or IL-4 11
On day 28 after primary infection, mice were challenged with wt RSV. 12
During secondary viral challenge, mice primed with rRSV/IFN-γ showed 13 significantly enhanced and sustained weight loss compared to mice primed with 14 wt RSV or rRSV/IL-4 ( Fig. 2A ). This weight loss was associated with an early 15 boost in total BAL cell numbers ( + cells during challenge (Fig. 4A, B) . No 12 IL-4 producing CD8 + cells were detected (data not shown), nor were there 13 significant peptide-specific TNF-α producing cells. 14 The rate of appearance and levels of RSV-specific immunoglobulin during 15 primary infection was unaffected by virally expressed IL-4 or IFN-γ (Fig. 5A) . 16
However, on day 15 of primary infection, expression of IL-4 significantly boosted 17
IgG1 and depressed IgG2a responses to RSV (Fig. 5B) . By contrast, expression 18 of IFN-γ depressed IgG1 responses on day 15 of primary infection (Fig. 5B) . 19 During secondary challenge with RSV, mice initially infected with rRSV/IFN-γ had 20 depressed levels of total RSV specific immunoglobulin (Fig. 5C ) while expression 21 of IL-4 resulted in a marginal increase of the antibodies. Expression of IL-4 duringprimary infection tended to boost IgG1 responses during secondary challenge; 1 while expression of IFN-γ led to some reduction in IgG2a responses (Fig. 5D) . 2
The influence of recombinant RSV infection on challenge with influenza A 3
To determine whether the effects were specific to RSV, we tested the 4 effect of rRSV on challenge with influenza A. Mice were infected with wt RSV, 5 rRSV/IFN-γ, rRSV/IL-4 or left naive; four weeks later mice were challenged i.n. 6 with 5 HA units of the X31 strain of influenza A, and groups of mice harvested on 7 days 3, 8 and 16 after challenge. 8
Mice that had received wt RSV or rRSV/IL-4 showed a faster recovery 9 from influenza infection induced weight loss than naïve mice or mice that had 10 been primed with rRSV/IFN-γ (Fig. 6A) . Influenza titres in all 4 groups were 11 similar on day 3 and day 8 post challenge, and RSV-L gene was not detectable 12 prior to, or during challenge (data not depicted). 13 BAL was performed on days 3, 8 and 16 post challenge. Total viable cell 14 counts showed that cellular infiltration was greatest in all groups on day 8. Mice 15 primed with rRSV/IFN-γ showed significantly increased BAL cell counts on d3 16
and d8 compared to mice treated in other ways (data not depicted and Fig. 6B ). 17
Conversely, mice primed with rRSV/IL-4 showed reduced cell numbers on day 8 18 post challenge compared to other mice (Fig. 6B ). Primary infection with 19 recombinant RSV had no significant effect on anti-influenza or anti-RSV antibody 20 titres (Fig. 6C) . 21
At d8 p.i., the majority of BAL cells in naïve mice or mice primed with wt 22 RSV or rRSV/IFN-γ were CD8 + T cells (Fig. 6E) . CD8 + T cell levels were similar 23 in naïve mice or mice infected with rRSV/IL-4 whilst CD4 + T cell levels were 1 slightly higher in mice primed with RSV/IL-4 (Fig. 6D) . However, rRSV/IL-4 2 priming lead to a significant increase in the number of eosinophils present in the 3 BAL both at day 3 (data not depicted) and day 8 post challenge (Fig. 6F) . At day 4 8 post challenge, elevated levels of BAL IL-4 ( Fig. 6G) and IL-5 (Fig. 6H) were 5 seen in mice primed rRSV/IL-4, and of IFN-γ in mice primed with rRSV/IFN-γ (Fig.  6 6I). Another possibility is that the recombinant RSV lead to persistent infection 18 (26) and thus to persistent production of the encoded cytokine. However, we 19 were unable to detect RSV L gene at any time later than day 12 after primary 20 infection with the recombinants using TaqMan RT-PCR. Further, RSV-F and NS2 21 genes (which have a higher transcriptional frequency) were undetectable prior 22 too or during influenza re-challenge (data not depicted). We ascribe the absence 23 of persistence to the use of recombinant RSV vectors instead of the strains usedin the previous study, and believe that persistence of recombinant virus is not 1 responsible for the altered phenotype observed during secondary challenge. 2
Rather, we propose that innate and acquired immune responses to secondary 3 challenge were modified by local antigenic and cytokine 'imprinting' resulting from 4 the primary infection. 5
This work is of interest because it shows that cytokine delivery by viral 6 vectors has an effect on the target organ, not only during the initial primary 7 infection but also during challenge with the same pathogen. Furthermore, 8 cytokine delivery can skew the immune environment in the lung so that 9 heterologous infections are also affected, and Th1 skewing is not always 10 beneficial to the safe and effective clearance of viral infections. 
